FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

1,117 letters match. Newest first.

  1. Ningbo Poplar Daily-Use

    FDA warned Ningbo Poplar Daily-Use that its OTC drugs had manufacturing quality failures in testing, component identity checks, and stability data.

    High risk
  2. Madhu Instruments Private Limited

    FDA cites Madhu Instruments in New Delhi for insanitary conditions in sterile drug manufacturing and places it on import alert.

    High risk
  3. QuVa Pharma, Inc.

    FDA warned QuVa Pharma, a sterile drug outsourcing facility in Bloomsbury, NJ, of mold in its cleanest filling area and other CGMP failures.

    High risk
  4. Lucky K.T. Co., Inc.

    FDA warns Lucky K.T. noodle maker over insanitary conditions, missing food safety plan, undeclared wheat.

    High risk
  5. Curtis Jacquot dba Pacific BioLogic Co.

    Pacific BioLogic's dietary supplements had manufacturing violations and disease claims making them unapproved drugs.

    High risk
  6. Perfection Bakeries Inc., dba Aunt Millie’s Bakeries

    Perfection Bakeries, dba Aunt Millie’s, recalled Our Family white hot dog buns because the label did not declare sesame.

    High risk
  7. Battle Creek Co-op/CHS, LLC dba Progressive Nutrition

    Progressive Nutrition's cattle feed contained excess urea linked to 17 cattle deaths, with preventive-control and medicated-feed violations.

    High risk
  8. Les Importations Herbasanté Inc.

    Canadian contract maker of homeopathic drugs, including children's products, skipped ingredient testing and process validation, FDA says.

    High risk
  9. Inmar Supply Chain Solutions, LLC

    FDA found severe rodent infestation at Inmar warehouse, adulterating stored foods, over-the-counter drugs, and devices.

    High risk
  10. Nantong Furuida Packaging Products Co., Ltd.

    Nantong Furuida, an over-the-counter drug manufacturer, failed required manufacturing controls and methanol checks, leading to an FDA import alert.

    High risk
  11. S & J International Enterprises Public Company Limited

    FDA cited S & J International Enterprises for CGMP violations, data integrity failures, and limiting access to records during a drug inspection.

    High risk
  12. Mei Lan Thailand Co., Ltd.

    Mei Lan Thailand, an API drug manufacturer, refused an FDA inspection and was placed on Import Alert 55-03.

    High risk
  13. Glicerinas Industriales, S.A. de C.V.

    FDA warned Glicerinas Industriales over CGMP failures in repackaged glycerin and propylene glycol, including DEG/EG testing and particulate contamination.

    High risk
  14. ReConserve Inc.

    FDA warned ReConserve Inc. that animal-food ingredients stored outdoors uncovered were contaminated and its preventive controls were inadequate.

    High risk
  15. Comercializadora Internacional Piscicola New Your S.A

    Colombian tilapia processor's HACCP plan omits Clostridium botulinum and drug-residue hazards, FDA says after remote assessment.

    High risk
  16. Prime Lab LLC

    Prime Lab LLC failed U.S. drug manufacturing quality rules for over-the-counter hand soaps and sanitizers, including raw-material testing and shared toxic equipment.

    High risk
  17. Woorilife & Health

    Woorilife & Health, a South Korean OTC drug maker, failed to test high-risk ingredients for DEG/EG and lacked quality-unit oversight.

    High risk
  18. MiMedx Group, Inc.

    FDA cites MiMedx for marketing placental product AXIOFILL without BLA or IND and for CGMP failures.

    High risk
  19. Deymed Diagnostic s.r.o.

    Deymed Diagnostic s.r.o.'s BrainFeedback Pro, TruScan LT, and DuoMAG NL devices had quality system violations in design, complaints, production, and records.

    Medium
  20. Kimera Labs, Inc.

    FDA warns Kimera Labs over unapproved exosome and amniotic fluid products and serious sterile manufacturing failures.

    High risk
  21. Inopak, Ltd.

    Inopak, Ltd. was warned of CGMP (current good manufacturing practice) violations after inspection: poor quality oversight of contract-made hand sanitizer and missing stability testing.

    High risk
  22. Lone Star Botanicals Inc.

    FDA cited Lone Star Botanicals for unsanitary ready-to-eat seasonings and unapproved drug claims for Dr. Botanical Health products.

    High risk
  23. Wipro Unza Singapore Private, Limited

    FDA cites Wipro Unza Singapore for refusing OTC hand sanitizer records, leading to import alert.

    High risk
  24. Patcos Cosmetics Pvt. Ltd.

    Patcos Cosmetics, an Indian OTC drug maker, failed to test high-risk ingredients for DEG/EG and lacked quality-unit oversight.

    High risk
  25. Omeza LLC

    FDA warned Omeza LLC over mold, insects and animal waste in drug manufacturing areas and unapproved nonprescription drugs.

    High risk
  26. Dextrum Laboratories Inc.

    FDA found Dextrum Laboratories, an over-the-counter drug contract manufacturer, failed identity testing, toxic glycol checks, water monitoring, and process validation.

    High risk
  27. US Gulf Coast Trading Co., Inc.

    US Gulf Coast Trading Co. warehouse in Houston held food amid widespread rodent filth and insanitary conditions.

    High risk
  28. Colonial Dames Company, Ltd

    FDA warns Colonial Dames of manufacturing violations and unapproved acne drug claims for Oxygenetix.

    High risk
  29. Cooperstown Cheese Company, LLC

    FDA found Listeria monocytogenes in Cooperstown Cheese's ready-to-eat raw milk cheese facility and cited repeated sanitation failures.

    High risk
  30. Sudesan Temizlik Urunleri Ve Ambalaj Sanaryi Ticaret Anomin Sirketi

    FDA warns Turkish hand sanitizer maker Sudesan of CGMP violations and adulterated drugs.

    High risk
  31. Terragene S.A.

    Terragene S.A. made sterilization indicator devices with complaint-handling and MDR failures and uncleared extended-cycle claims.

    High risk
  32. Sonesta Medical AB

    FDA warned Sonesta Medical AB that its radiographic and cystometric tables violated device quality system rules.

    Medium
  33. Desserts by Helen, Inc.

    FDA cited Desserts by Helen for unsanitary conditions and cleaning failures at its Louisville ready-to-eat bakery.

    High risk
  34. Fresenius Medical Care AG & Co. KGaA

    FDA warns Fresenius over delayed fixes and reporting for PCB leaching from silicone tubing in hemodialysis machines.

    High risk
  35. Novid Group, Inc.

    FDA told Novid Group its OTC nasal spray, novid NASAL SPRAY, is an unapproved new drug and misbranded.

    High risk
  36. Nutra Blend, LLC subsidiary of Land O’Lakes

    Nutra Blend's medicated calf feed contained unintended monensin, killing calves and prompting a recall.

    High risk
  37. Dr. Berne’s Whole Health Products

    Dr. Berne’s MSM eye drops and mist are unapproved new drugs; a tested lot had microbial contamination.

    High risk
  38. Intas Pharmaceuticals Limited

    FDA cited Intas Pharmaceuticals for CGMP violations, including manipulated visual inspection records and inadequate sterile-drug controls.

    High risk
  39. AmLion Toothpaste Mfg. Sdn. Bhd.

    FDA cites AmLion Toothpaste in Malaysia for CGMP failures, including no testing of glycerin and sorbitol for DEG/EG; firm stays on import alert.

    High risk
  40. Cipla Limited

    FDA warned Cipla about unresolved albuterol inhaler delivery complaints and contamination in sterile manufacturing at its Indore site.

    High risk
  41. Cerci Kozmetik Ve Otel Ekipmanlari Pazarlama Ic Ve Dis Ticaret Limited Sirketi

    FDA: Turkish OTC drug maker Cerci shipped to the U.S. without finished-product identity and strength testing.

    High risk
  42. Xiamen Wally Bath Manufacture Co., Ltd.

    FDA warns Xiamen Wally Bath over current good manufacturing practice failures for over-the-counter hand sanitizer, including raw material and release testing gaps.

    High risk
  43. Wan-Gee Foods, Inc.

    FDA found insanitary conditions and missing food safety controls at Wan-Gee Foods’ noodle plant.

    High risk
  44. National Chemical Laboratories

    National Chemical Laboratories’ OTC topical drugs were adulterated after FDA found manufacturing quality violations, including untested BZK and weak quality oversight.

    High risk
  45. Brenntag Great Lakes, LLC

    Brenntag Great Lakes failed to prevent cross-contamination of OTC hand sanitizer made on equipment shared with industrial chemicals.

    High risk
  46. Elemental Herbs Inc. d/b/a ALL good

    Elemental Herbs (ALL good) cited for CGMP failures and unapproved, misbranded Goop Skin Recovery Balm.

    High risk
  47. Wello Inc.

    FDA cited Wello Inc. for misbranded welloStationX devices because labels lacked unique device identifiers and required GUDID data were not submitted.

    Low
  48. Saruhan Kimya Ve Temizlik Urunleri Sanayi Ticaret Anonim Sirketi Corlu Subesi

    FDA found manufacturing violations at Turkish OTC drug maker, including missing identity, release, and stability testing for hand sanitizers.

    High risk
  49. Independent Seafoods Panama, S.A. dba Panama Artisanal Seafoods FQ

    FDA warned Independent Seafoods Panama over missing written seafood safety plans for fresh and histamine fish.

    High risk
  50. PESCAMOZ LDA

    FDA says PESCAMOZ lacked required seafood safety plans for tuna and swordfish, calling products adulterated.

    High risk